OCM
SLDB icon

Osbon Capital Management’s Solid Biosciences SLDB Stock Holding History

Osbon Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.61K Hold
501
– – ﹤0.01% 384
2025
Q4 		$2.83K Buy
+501
New +$2.71K ﹤0.01% 297

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Osbon Capital Management's SLDB Position: Q1 2026 in Review

Osbon Capital Management held its Solid Biosciences (SLDB) position steady in Q1 2026 at 501 shares worth $3.61K. The position accounts for ﹤0.01% of the portfolio, ranked #384.

Osbon Capital Management first reported a position in SLDB in Q4 2025 and has held it in 2 quarters since. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Osbon Capital Management held 501 shares of Solid Biosciences worth $3.61K as of Q1 2026.
  • Osbon Capital Management left its Solid Biosciences share count unchanged in Q1 2026.
  • Solid Biosciences made up ﹤0.01% of Osbon Capital Management's portfolio in Q1 2026, its #384 holding.
  • Osbon Capital Management first reported a position in Solid Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Osbon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.